| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -54,848 | -31,257 | 21,631 | -216,054 |
| Depreciation and amortization | 22,201 | 22,373 | 22,740 | 46,514 |
| Non-cash interest | 2,433 | 2,391 | 2,309 | 61,557 |
| Amortization of deferred financing costs | 137 | 137 | 138 | 4,959 |
| Losses from investments in investees | -2 | -17 | -3 | -9 |
| Equity-based compensation employees and non-employees | 2,735 | 2,917 | 2,969 | 4,828 |
| Impairment charges | NaN | 0 | 1,007 | NaN |
| Realized gain on disposal of fixed assets and sales of equity securities | 34 | -601 | -12 | 3,858 |
| Change in fair value of equity securities and derivative instruments | -3,934 | 824 | 287 | -1,734 |
| Loss on conversion convertible senior notes | NaN | 0 | NaN | NaN |
| Inducement expense and loss on debt conversion | NaN | 0 | 0 | 32,647 |
| Change in fair value of contingent consideration | NaN | 0 | NaN | NaN |
| Deferred income tax (benefit) provision | -7,890 | -10,149 | 18,287 | -23,137 |
| Gain on sale of assets | NaN | 0 | 101,576 | NaN |
| Accounts receivable, net | -9,526 | -6,709 | -4,389 | -19,115 |
| Inventory, net | -191 | -1,173 | -624 | 5,915 |
| Other current assets and prepaid expenses | -6,969 | 4,137 | -1,035 | 2,318 |
| Other assets | 126 | -121 | -412 | 510 |
| Accounts payable | 3,496 | -17,060 | -5,244 | 8,087 |
| Foreign currency measurement | 126 | 4,843 | -2,676 | -1,989 |
| Accrued expenses and other liabilities | -8,162 | -3,776 | -420 | -43,643 |
| Net cash used in operating activities | -19,310 | -25,921 | -34,647 | -117,974 |
| Investments in investees | 0 | 0 | 7,665 | NaN |
| Proceeds from sale of equity securities | -51,655 | NaN | 0 | 51,655 |
| Purchase of marketable securities | NaN | NaN | 0 | NaN |
| Proceeds from sale of investments | NaN | 52,182 | NaN | NaN |
| Proceeds from the sale of property, plant and equipment | 33 | 93 | 13 | 181 |
| Capital expenditures | 1,833 | 2,666 | 3,135 | 6,477 |
| Investments in investees | NaN | NaN | NaN | 7,665 |
| Proceeds from labcorp sales including escrow released | NaN | NaN | 197,770 | NaN |
| Proceeds from labcorp sale | NaN | 197,770 | NaN | NaN |
| Net cash (used in) provided by investing activities | -1,800 | -2,046 | 194,648 | 37,694 |
| Issuance of 3.00 convertible senior notes, net (including related parties) | NaN | 0 | 0 | 0 |
| Issuance of 2044 notes | NaN | 0 | 0 | NaN |
| Debt issuance costs | NaN | 0 | 0 | 0 |
| Share repurchase | 4,767 | 13,507 | 15,278 | 18,255 |
| Proceeds from the exercise of common stock options | 0 | -133 | 0 | -123 |
| Repurchase of 2029 convertible notes | NaN | 0 | 62,208 | NaN |
| Borrowings on lines of credit | 8,486 | 8,528 | 7,869 | 16,636 |
| Repayments of lines of credit | 8,876 | 13,227 | 8,797 | 19,387 |
| Settlement of convertible notes | 0 | 0 | -62,208 | 62,382 |
| Net cash used in financing activities | -5,157 | -18,339 | -16,206 | -83,511 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | -908 | 174 | -316 | 3,571 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -27,175 | -46,132 | 143,479 | -160,220 |
| Cash, cash equivalents and restricted cash at beginning of period | 382,742 | 428,874 | 445,615 | NaN |
| Cash, cash equivalents and restricted cash at end of period | 355,567 | 382,742 | 428,874 | NaN |
OPKO HEALTH, INC. (OPK)
OPKO HEALTH, INC. (OPK)